1
|
Magalhães M, Domínguez-Martín EM, Jorge J, Gonçalves AC, Massenzio F, Spigarelli R, Ribeiro-Rodrigues T, Catarino S, Girão H, Monti B, Spisni E, Ferreira L, Oliveira PJ, Efferth T, Rijo P, Cabral C. Unveiling the antitumor mechanism of 7α-acetoxy-6β-hydroxyroyleanone from Plectranthus hadiensis in glioblastoma. JOURNAL OF ETHNOPHARMACOLOGY 2024; 335:118689. [PMID: 39128799 DOI: 10.1016/j.jep.2024.118689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/12/2024] [Revised: 07/30/2024] [Accepted: 08/09/2024] [Indexed: 08/13/2024]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Glioblastoma (GB) is the most aggressive and prevalent glioma within the central nervous system. Despite considerable efforts, GB continues to exhibit a dismal 5-year survival rate (∼6%). This is largely attributed to unfavorable prognosis and lack of viable treatment options. Therefore, novel therapies centered around plant-derived compounds emerge as a compelling avenue to enhance patient survival and well-being. The South African species, Plectranthus hadiensis Schweinf. (P. hadiensis), a member of the Lamiaceae family, has a history of use in traditional medicine for treating a range of diseases, including respiratory, digestive, and liver disorders. This species exhibits diverse biological activities, such as anti-inflammatory and antitumoral properties, likely attributed to its rich composition of naturally occurring diterpenes, like the abietane diterpene, 7α-acetoxy-6β-hydroxyroyleanone (Roy). Roy has demonstrated promising antitumor effects in various cancer cell lines, making it a compelling candidate for further investigation into its mechanisms against GB. AIM OF THE STUDY This study aims to investigate the antitumor activity and potential mechanism of Roy, a natural lead compound, in GB cells. MATERIAL AND METHODS Roy was isolated from the acetonic extract of P. hadiensis and its antitumor mechanism was assessed in a panel of human GB cell lines (U87, A172, H4, U373, and U118) to mimic tumor heterogeneity. Briefly, the impact of Roy treatment on the metabolic activity of cells was evaluated by Alamar Blue® assay, while cell death, cell cycle regulation, mitochondrial membrane potential, and activated caspase-3 activity were evaluated by flow cytometry. Measurement of mRNA levels of target genes was performed by qPCR, while protein expression was assessed by Western blotting. Cell uptake and impact on mitochondrial morphology were evaluated by confocal microscopy. RESULTS Roy induced G2/M cell cycle arrest, mitochondrial fragmentation, and apoptosis by inhibiting the expression of anti-apoptotic proteins and increasing the levels of activated caspase-3. The concentrations of Roy needed to achieve significant inhibitory outcomes were notably lower (6-9 fold) than those of temozolomide (TMZ), the standard first-line treatment, for achieving comparable effects. In addition, at low concentrations (16 μM), Roy affected the metabolic activity of tumor cells while having no significant impact on non-tumoral cells (microglia and astrocytes). CONCLUSION Overall, Roy demonstrated a robust antitumor activity against GB cells offering a promising avenue for the development of novel chemotherapeutic approaches.
Collapse
Affiliation(s)
- Mariana Magalhães
- University of Coimbra, Institute for Interdisciplinary Research, Doctoral Programme in Experimental Biology and Biomedicine (PDBEB), Portugal; University of Coimbra, CNC-Center for Neuroscience and Cell Biology, Coimbra, Portugal; University of Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR), Clinic Academic Center of Coimbra (CACC), Faculty of Medicine, Coimbra, Portugal; University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Portugal
| | - Eva María Domínguez-Martín
- CBIOS-Universidade Lusófona's Research Center for Biosciences & Health Technologies, Lisbon, Portugal; Departamento de Ciencias Biomédicas, Facultad de Farmacia, Universidad de Alcalá de Henares, Madrid, Spain
| | - Joana Jorge
- University of Coimbra, Laboratory of Oncobiology and Hematology, University Clinic of Hematology and Applied Molecular Biology, Faculty of Medicine, Coimbra, Portugal; University of Coimbra, ICBR, Group of Environment Genetics and Oncobiology (CIMAGO)-Faculty of Medicine, Coimbra, Portugal
| | - Ana Cristina Gonçalves
- University of Coimbra, Laboratory of Oncobiology and Hematology, University Clinic of Hematology and Applied Molecular Biology, Faculty of Medicine, Coimbra, Portugal; University of Coimbra, ICBR, Group of Environment Genetics and Oncobiology (CIMAGO)-Faculty of Medicine, Coimbra, Portugal
| | - Francesca Massenzio
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - Renato Spigarelli
- Department of Biological, Geological and Environmental Sciences, University of Bologna, Bologna, Italy
| | - Teresa Ribeiro-Rodrigues
- University of Coimbra, CNC-Center for Neuroscience and Cell Biology, Coimbra, Portugal; University of Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR), Clinic Academic Center of Coimbra (CACC), Faculty of Medicine, Coimbra, Portugal; University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Portugal
| | - Steve Catarino
- University of Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR), Clinic Academic Center of Coimbra (CACC), Faculty of Medicine, Coimbra, Portugal; University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Portugal
| | - Henrique Girão
- University of Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR), Clinic Academic Center of Coimbra (CACC), Faculty of Medicine, Coimbra, Portugal; University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Portugal
| | - Barbara Monti
- Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
| | - Enzo Spisni
- Department of Biological, Geological and Environmental Sciences, University of Bologna, Bologna, Italy
| | - Lino Ferreira
- University of Coimbra, CNC-Center for Neuroscience and Cell Biology, Coimbra, Portugal; University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Portugal; University of Coimbra, Faculty of Medicine, Coimbra, Portugal
| | - Paulo J Oliveira
- University of Coimbra, CNC-Center for Neuroscience and Cell Biology, Coimbra, Portugal; University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Portugal
| | - Thomas Efferth
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany
| | - Patrícia Rijo
- CBIOS-Universidade Lusófona's Research Center for Biosciences & Health Technologies, Lisbon, Portugal; Faculty of Pharmacy, Instituto de Investigação Do Medicamento (iMed.ULisboa), University of Lisbon, Lisbon, Portugal
| | - Célia Cabral
- University of Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR), Clinic Academic Center of Coimbra (CACC), Faculty of Medicine, Coimbra, Portugal; University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Portugal; University of Coimbra, Centre for Functional Ecology, Department of Life Sciences, Coimbra, Portugal.
| |
Collapse
|
2
|
Ren C, Li Y, Du P, Zhang X, Xue W, Zhang C. Ethical requirements of instructions for authors of complementary and alternative medicine journals: a cross-sectional study. BMC Med Ethics 2024; 25:77. [PMID: 39003488 PMCID: PMC11245789 DOI: 10.1186/s12910-024-01077-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Accepted: 07/02/2024] [Indexed: 07/15/2024] Open
Abstract
BACKGROUND Medical research in complementary and alternative medicine (CAM) has increased recently, raising ethical concerns about the moral status of CAM. Medical academic journals are responsible for conducting ethical review (ER) of manuscripts to protect the interests of human subjects and to make ethical results available before deciding to publish. However, there has been no systematic analysis of the ER in CAM journals. This study is aim to evaluate the current status of ethical requirements and compliance in CAM journals. METHODS This is a cross-sectional study. We reviewed instructions for authors (IFAs) of CAM journals included in the Journal Citation Reports (2021) ( https://jcr.clarivate.com ) for general information and requirements for ER. We also browsed the manuscripts regarding randomized controlled trials published by CAM journals in Q1 and Q2 section from January to June, 2023, to check the actual situation of ethical requirement. Descriptive statistics and Fisher's exact test were used for statistical analysis. RESULTS 27 journals and 68 manuscripts were ultimately included. 92.6% (25/27) IFAs included keywords of ER, indicating the presence of ethical considerations. However, no specific ER was required for CAM (n = 0). We categorized journals by Geographic origin, JCR section, Year of electronic JCR, Types of studies, % of OA Gold to explore the factors that could influence CAM journals to have certain ethical review policies. The results showed there was no statistical significance in certain ethical review policy in any classification of journals (p > 0.05). All RCT manuscripts included in the study generally met the requirements of the published journals for ethical review. CONCLUSIONS All IFAs discussed ER, but the content was scattered, unfocused, and there were no specific ER requirements regarding CAM. Although the manuscripts basically met the requirements of the journal, it was not possible to get closer to the process of ER in the manuscript. To ensure full implementation of these policies in the future, CAM journals should require authors to provide more details, or to form a list of items necessary for CAM ethical review.
Collapse
Affiliation(s)
- Chenyu Ren
- Dongzhimen Hospital, Beijing University of Chinese Medicine, 5 Haiyuncang Street, Dongcheng District, Beijing, 100070, China
| | - Yixuan Li
- Dongzhimen Hospital, Beijing University of Chinese Medicine, 5 Haiyuncang Street, Dongcheng District, Beijing, 100070, China
| | - Peipei Du
- Dongzhimen Hospital, Beijing University of Chinese Medicine, 5 Haiyuncang Street, Dongcheng District, Beijing, 100070, China
| | - Xuebin Zhang
- Dongzhimen Hospital, Beijing University of Chinese Medicine, 5 Haiyuncang Street, Dongcheng District, Beijing, 100070, China
| | - Wanjun Xue
- Dongzhimen Hospital, Beijing University of Chinese Medicine, 5 Haiyuncang Street, Dongcheng District, Beijing, 100070, China.
| | - Chi Zhang
- Dongzhimen Hospital, Beijing University of Chinese Medicine, 5 Haiyuncang Street, Dongcheng District, Beijing, 100070, China.
- Institute for Brain Disorders, Beijing University of Chinese Medicine, Beijing, China.
| |
Collapse
|
3
|
Higham HE, Morgan L, Cooper C, Marshall J, Mawer A, Jackson S, Lopez-Ramon R, Hughes E, Richards D, McShane H, Fullerton JN. Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2. Br J Clin Pharmacol 2024; 90:1586-1599. [PMID: 37903635 DOI: 10.1111/bcp.15949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 10/04/2023] [Accepted: 10/15/2023] [Indexed: 11/01/2023] Open
Abstract
AIMS The influence of human factors on safety in healthcare settings is well established, with targeted interventions reducing risk and enhancing team performance. In experimental and early phase clinical research participant safety is paramount and safeguarded by guidelines, protocolized care and staff training; however, the real-world interaction and implementation of these risk-mitigating measures has never been subjected to formal system-based assessment. METHODS Independent structured observations, systematic review of study documents, and interviews and focus groups were used to collate data on three key tasks undertaken in a clinical research facility (CRF) during a SARS CoV-2 controlled human infection model (CHIM) study. The Systems Engineering Initiative for Patient Safety (SEIPS) was employed to analyse and categorize findings, and develop recommendations for safety interventions. RESULTS High levels of team functioning and a clear focus on participant safety were evident throughout the study. Despite this, latent risks in both study-specific and CRF work systems were identified in all four SEIPS domains (people, environment, tasks and tools). Fourteen actionable recommendations were generated collaboratively. These included inter-organization and inter-study standardization, optimized checklists for safety critical tasks, and use of simulation for team training and exploration of work systems. CONCLUSIONS This pioneering application of human factors techniques to analyse work systems during the conduct of research in a CRF revealed risks unidentified by routine review and appraisal, and despite international guideline adherence. SEIPS may aid categorization of system problems and the formulation of recommendations that reduce risk and mitigate potential harm applicable across a trials portfolio.
Collapse
Affiliation(s)
- Helen E Higham
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
- Department of Anaesthetics, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Lauren Morgan
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
| | - Cushla Cooper
- NIHR Oxford Clinical Research Facility, University of Oxford, Oxford, UK
| | - Julia Marshall
- Department of Paediatrics, University of Oxford, Oxford, UK
| | - Andrew Mawer
- Department of Paediatrics, University of Oxford, Oxford, UK
| | - Susan Jackson
- Department of Paediatrics, University of Oxford, Oxford, UK
| | | | - Eileen Hughes
- Department of Paediatrics, University of Oxford, Oxford, UK
| | - Duncan Richards
- NIHR Oxford Clinical Research Facility, University of Oxford, Oxford, UK
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK
| | - Helen McShane
- Department of Paediatrics, University of Oxford, Oxford, UK
| | - James N Fullerton
- NIHR Oxford Clinical Research Facility, University of Oxford, Oxford, UK
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK
- Department of Clinical Pharmacology and Therapeutics, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| |
Collapse
|
4
|
Avinger AM, Sibold HC, Campbell G, Abernethy E, Bourgeois J, McClary T, Blee S, Dixon M, Harvey RD, Pentz RD. Improving oncology first-in-human and Window of opportunity informed consent forms through participant feedback. BMC Med Ethics 2023; 24:12. [PMID: 36803249 PMCID: PMC9938963 DOI: 10.1186/s12910-023-00890-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Accepted: 01/31/2023] [Indexed: 02/21/2023] Open
Abstract
BACKGROUND Although patient advocates have developed templates for standard consent forms, evaluating patient preferences for first in human (FIH) and window of opportunity (Window) trial consent forms is critical due to their unique risks. FIH trials are the initial use of a novel compound in study participants. In contrast, Window trials give an investigational agent over a fixed duration to treatment naïve patients in the time between diagnosis and standard of care (SOC) surgery. Our goal was to determine the patient-preferred presentation of important information in consent forms for these trials. METHODS The study consisted of two phases: (1) analyses of oncology FIH and Window consents; (2) interviews of trial participants. FIH consent forms were analyzed for the location(s) of information stating that the study drug has not been tested in humans (FIH information); Window consents were analyzed for the location(s) of information stating the trial may delay SOC surgery (delay information). Participants were asked about their preferred placement of the information in their own trial's consent form. The location of information in the consent forms was compared to the participants' suggestions for placement. RESULTS 34 [17 FIH; 17 Window] of 42(81%) cancer patients approached participated. 25 consents [20 FIH; 5 Window] were analyzed. 19/20 FIH consent forms included FIH information, and 4/5 Window consent forms included delay information. 19/20(95%) FIH consent forms contained FIH information in the risks section 12/17(71%) patients preferred the same. Fourteen (82%) patients wanted FIH information in the purpose, but only 5(25%) consents mentioned it there. 9/17(53%) Window patients preferred delay information to be located early in the consent, before the "Risks" section. 3/5(60%) consents did this. CONCLUSIONS Designing consents that reflect patient preferences more accurately is essential for ethical informed consent; however, a one-size fits all approach will not accurately capture patient preferences. We found that preferences differed for FIH and Window trial consents, though for both, patients preferred key risk information early in the consent. Next steps include determining if FIH and Window consent templates improve understanding.
Collapse
Affiliation(s)
- Anna M Avinger
- Wake Forest University School of Medicine, 475 Vine St, Winston-Salem, NC, 27101, USA
| | - Hannah Claire Sibold
- Duke University School of Medicine, 40 Duke Medicine Cir., Durham, NC, 27710, USA
| | - Gavin Campbell
- Emory University Rollins School of Public Health, 1518 Clifton Rd, Atlanta, GA, 30322, USA
| | - Eli Abernethy
- Duke University School of Medicine, 40 Duke Medicine Cir., Durham, NC, 27710, USA
| | - John Bourgeois
- Winship Cancer Institute of Emory University, 1365 E Clifton Rd, Atlanta, GA, 30322, USA
| | - Tekiah McClary
- South University Orlando Campus, 5900 Lake Ellenor Dr., Orlando, FL, 32809, USA
| | - Shannon Blee
- Creighton University Medical School, 2621 Burt Street, Omaha, NE, 68178, USA
| | - Margie Dixon
- Winship Cancer Institute of Emory University, 1365 E Clifton Rd, Atlanta, GA, 30322, USA.,Emory University School of Medicine, 201 Dowman Dr., Atlanta, GA, 30322, USA
| | - R Donald Harvey
- Winship Cancer Institute of Emory University, 1365 E Clifton Rd, Atlanta, GA, 30322, USA.,Emory University School of Medicine, 201 Dowman Dr., Atlanta, GA, 30322, USA
| | - Rebecca D Pentz
- Winship Cancer Institute of Emory University, 1365 E Clifton Rd, Atlanta, GA, 30322, USA. .,Emory University School of Medicine, 201 Dowman Dr., Atlanta, GA, 30322, USA. .,Winship Cancer Institute, 2004 Ridgewood Dr., Office 301, Atlanta, GA, 30322, USA.
| |
Collapse
|
5
|
Gerdfaramarzi MS, Bazmi S, Kiani M, Afshar L, Fadavi M, Enjoo SA. Ethical challenges of cord blood banks: a scoping review. J Med Life 2022; 15:735-741. [PMID: 35928362 PMCID: PMC9321494 DOI: 10.25122/jml-2021-0162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2021] [Accepted: 09/22/2021] [Indexed: 11/17/2022] Open
Abstract
Cord blood is a rich source of hematopoietic stem cells used to treat many diseases of blood origin. Thus, storage banks were created to store and provide umbilical cord cells. With the development of diagnostic and therapeutic technologies and techniques in medicine, ethical issues have also become more widespread and complex. After the creation of the cord blood banks, efforts were made to address the ethical issues associated with such banks. The present study attempts to identify the ethical challenges in these banks in the published studies. Databases including PubMed, Scopus, Web of Science (WOS), Embase, Proquest, and Google Scholar were searched from January 1996 to January 2021. Then, the ethical challenges of the cord blood bank were extracted from the results section using thematic content analysis. 22 studies were selected based on inclusion and exclusion criteria. The ethical challenges raised in the studies included private or public ownership of the bank, fair access to banking services, informed and voluntary consent, failure to provide sufficient information to individuals about the process, confidentiality of user's information, conflict of interest of bank founders (who are commonly doctors). The findings of this study indicated that there are serious ethical concerns regarding umbilical cord blood banks. Responding clearly to these ethical challenges calls for the attention of policymakers and medical ethics professionals; this will require a clear statement of the various aspects of these banks for society.
Collapse
Affiliation(s)
- Madjid Soltani Gerdfaramarzi
- Department of Medical Ethics, School of Traditional Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Shabnam Bazmi
- Department of Medical Ethics, School of Traditional Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mehrzad Kiani
- Department of Medical Ethics, School of Traditional Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Leila Afshar
- Department of Medical Ethics, School of Traditional Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mohsen Fadavi
- Department of Medical Ethics, School of Traditional Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Seyed Ali Enjoo
- Department of Medical Ethics, School of Traditional Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran,Corresponding Author: Seyed Ali Enjoo, Department of Medical Ethics, School of Traditional Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. E-mail:
| |
Collapse
|
6
|
Drolet MJ, Girard K. Habiliter l’ergothérapeute-chercheur à résoudre les enjeux éthiques de la recherche. CANADIAN JOURNAL OF BIOETHICS 2020. [DOI: 10.7202/1073780ar] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
La recherche est une occupation propice à l’émergence d’enjeux éthiques, en outre parce qu’elle est liée à des conflits d’intérêts parfois difficiles à gérer et se réalise dans un contexte hautement compétitif qui valorise la performance. Alors que les enjeux éthiques de la pratique clinique de l’ergothérapie commencent à être documentés, les enjeux éthiques vécus par les chercheurs en ergothérapie et les moyens qu’ils utilisent pour gérer ces enjeux ne sont quasiment pas documentés. Cet article présente les résultats d’une étude qualitative qui a documenté les moyens (macro, méso et micro) qui sont proposés par des ergothérapeutes-chercheurs pour résoudre les enjeux éthiques de la recherche. Onze ergothérapeutes (n=11) ont participé à la recherche et partagent les moyens qu’ils utilisent ou envisagent pour gérer les enjeux éthiques de la recherche qu’ils vivent comme chercheur. Les moyens proposés par les ergothérapeutes rejoignent plusieurs moyens suggérés dans les écrits, quoique certains moyens proposés dans les écrits relatifs à la relation à établir avec les participants de recherche soient peu abordés par les participants, ce qui est surprenant compte tenu des valeurs humanistes au fondement de la profession d’ergothérapeute. Au final, cet article qui présente une synthèse à la fois des moyens répertoriés dans des écrits pour résoudre les enjeux éthiques de la recherche et ceux discutés par les participants vise à habiliter l’ergothérapeute-chercheur à résoudre les enjeux que pose la recherche académique tout en restant fidèle aux valeurs de la profession.
Collapse
Affiliation(s)
- Marie-Josée Drolet
- Département d’ergothérapie de l’Université du Québec à Trois-Rivières, Trois-Rivières, Canada
| | - Karoline Girard
- Bureau intégré de l’éthique, Centre intégré universitaire de santé et de services sociaux de la Mauricie et du Centre-du-Québec (CIUSSS-MCQ), Trois-Rivières, Canada
| |
Collapse
|
7
|
Trung LQ, Morra ME, Truong ND, Turk T, Elshafie A, Foly A, Hien Tam DN, Iraqi A, Hong Van TT, Elgebaly A, Ngoc TN, Vu TLH, Chu NT, Hirayama K, Karbwang J, Huy NT. A systematic review finds underreporting of ethics approval, informed consent, and incentives in clinical trials. J Clin Epidemiol 2017; 91:80-86. [PMID: 28866123 DOI: 10.1016/j.jclinepi.2017.08.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2016] [Revised: 07/23/2017] [Accepted: 08/18/2017] [Indexed: 11/26/2022]
Abstract
OBJECTIVES In this study, we aim to review researchers' reporting practices of the ethics statement, financial incentives, and local ethical committees' profile in their clinical trials. STUDY DESIGN AND SETTING A systematic search was done through top-ranked 50 medical journals (Scimago Ranking) to retrieve 2,000 latest publications. Only primary clinical trials were included with no restriction to language or participants. RESULTS Among the 927 included trials, 14 trials (1.5%) did not report an ethical statement and two-third (63%) did not completely report the investigated components (Institutional Review eBoard approval, Helsinki Declaration, and informed consent). Moreover, 21 trials (2.26%) reported motivational incentives with the method and amount of payment for participants. Of them, 15 trials offered monetary incentives to participants in different forms. In the remaining six trials, the incentives were mainly medical benefits. Only one trial reported the profile or quality of local Institutional Review Board. CONCLUSION A potential gap in the reporting practices of ethics statement and financial incentives was addressed in this review. Authors are urged to fully report all ethical components related to their study, including incentives and compensations plan. Medical journals are also recommended to implement further publication requirements concerning ethics reporting.
Collapse
Affiliation(s)
- Ly Quoc Trung
- Soc Trang Provincial Hospital, Soc Trang, 97000, Vietnam
| | | | - Nguyen Duc Truong
- Department of Obstetrics and Gynecology, FV Hospital, Ho Chi Minh City, 70000, Vietnam
| | - Tarek Turk
- Faculty of Medicine, Damascus University, Damascus, Syria
| | - Ahmed Elshafie
- Faculty of Medicine, Alexandria University, Alexandria, 21111, Egypt
| | - Amr Foly
- Faculty of Medicine, Cairo University, Cairo, 11562, Egypt
| | - Dao Ngoc Hien Tam
- University of Medicine and Pharmacy, Ho Chi Minh City, 70000, Vietnam
| | - Ahmed Iraqi
- House Officer Benha University Hospitals, Benha, 13738, Egypt
| | - Trinh Thi Hong Van
- Pham Ngoc Thach University of Medicine, Ho Chi Minh City, 70000, Vietnam
| | - Ahmed Elgebaly
- Faculty of Medicine, Al-Azhar University, Cairo, 11884, Egypt
| | - Tran Nhu Ngoc
- Pham Ngoc Thach University of Medicine, Ho Chi Minh City, 70000, Vietnam
| | | | - Ngan Thy Chu
- Lectrurer at Dong Nai Medical College, Bien Hoa City, 810000, Vietnam
| | - Kenji Hirayama
- Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Leading Graduate School Program and Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
| | - Juntra Karbwang
- Department of Clinical Product Development, Institute of Tropical Medicine (NEKKEN), Leading Graduate School Program and Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan
| | - Nguyen Tien Huy
- Department of Clinical Product Development, Institute of Tropical Medicine (NEKKEN), Leading Graduate School Program and Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan; Evidence Based Medicine Research Group, Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City, Vietnam.
| |
Collapse
|